Lilly and Dicerna enter RNAi collaboration; potential deal value tops $3.7bn
Eli Lilly & Co. partnered with Dicerna Pharmaceuticals Inc. to discover and develop RNAi therapies for cardio-metabolic diseases, neurodegeneration, and pain.
- Antisense, Oligonucleotides
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.